Q-omics provides the consensus-scored RPL23AP49 profile across patient tissues and cancer cell-line models. RPL23AP49 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, RPL23AP49 is differentially expressed in 9, with the highest sampling consensus in KICH. Additionally, RPL23AP49 RNA expression shows 14,646 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRP, KICH, and THYM as cancer lineages where RPL23AP49 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL23AP49 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL23AP49 survival associations across molecular data types. RPL23AP49 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL23AP49 RNA expression–survival associations across cancer types. High RPL23AP49 expression shows unfavorable associations in LUAD and CESC, but favorable associations in KIRP, UVM, LGG and MESO. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for RPL23AP49 RNA expression.
This table summarizes RPL23AP49 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL23AP49. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL23AP49 shows lower tumor expression in KICH, HNSC, STAD, BRCA, COAD and LUSC. The KICH box plot shows higher RPL23AP49 RNA expression in normal versus tumor tissue (log2 FC = −2.297, t-test p < 0.001).
This table shows molecular features associated with RPL23AP49 in patient tissues and cancer cell lines. In patient samples, RPL23AP49 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
